Lilly and Sankyo To Collaborate on Novel Oral Antithrombotic Compound
21-Dec-2000 -
Eli Lilly and Company (NYSE: LLY and TSE: 4857) and Sankyo Company, Ltd. (TSE:
4501), announced they have signed a letter of intent to collaborate on CS-747, a
potentially potent antiplatelet agent that blocks ADP receptors. CS-747 is being
tested in Phase I human clinical trials for its ...
Acute Coronary Syndrome
acute myocardial infarction
angina
+7